Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from EQS Group

17:30 EDT 23rd April 2018 | BioPortfolio

Here are the most relevant search results for "EQS Group" found in our extensive news archives from over 250 global news sources.

More Information about EQS Group on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about EQS Group for you to read. Along with our medical data and news we also list EQS Group Clinical Trials, which are updated daily. BioPortfolio also has a large database of EQS Group Companies for you to search.

Showing News Articles 1–25 of 393 from EQS Group

Monday 23rd April 2018

MorphoSys AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

MorphoSys AG / Total Voting Rights Announcement 23.04.2018 / 17:23 Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of total number of voting rights 1. Details of issuer MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany 2. Type of capital me...

Fresenius SE & Co. KGaA: Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius

Fresenius SE & Co. KGaA / Key word(s): Mergers & Acquisitions/Legal Matter Fresenius SE & Co. KGaA: Akorn, Inc. sues Fresenius for consummation of merger agreement after its termination by Fresenius 23-Apr-2018 / 16:53 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solel...

Eifelhöhen-Klinik AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

Eifelhöhen-Klinik AG / Preliminary announcement on the disclosure of financial statements 23.04.2018 / 10:34 Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ---------------------------...

MOLOGEN AG: Announcement of the new dates for the publication of the Annual Financial Statements 2017 and the 2018 Annual General Meeting

DGAP-News: MOLOGEN AG / Key word(s): Miscellaneous 23.04.2018 / 08:57 The issuer is solely responsible for the content of this announcement. PRESS RELEASE N 10 / 2018 of 23/04/2018 MOLOGEN AG: Announcement of the new dates for the publication of the Annual Financial Statements 2017 and the 2018 Annual General Meeting Berlin, 23 April 2018 - The biopharmaceutical company MOLOGEN AG ann...

Sunday 22nd April 2018

Fresenius SE & Co. KGaA: Fresenius terminates merger agreement with Akorn

Fresenius SE & Co. KGaA / Key word(s): Mergers & Acquisitions Fresenius SE & Co. KGaA: Fresenius terminates merger agreement with Akorn 22-Apr-2018 / 19:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Freseni...

Fresenius Medical Care confirms net income growth target, adjusts 2018 revenue growth target and releases preliminary Q1 figures

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Change in Forecast/Quarter Results 22.04.2018 / 17:19 The issuer is solely responsible for the content of this announcement. Adjusted revenue growth target in 2018 of 5 to 7% at constant currency expected (previously around 8%) mainly due to recent reduction in dosing of calcimimetic drugs Reconfirmed reported net income ...

Fresenius Medical Care AG & Co. KGaA adjusts its 2018 revenue growth target and confirms its net income growth target

Fresenius Medical Care AG & Co. KGaA / Key word(s): Change in Forecast Fresenius Medical Care AG & Co. KGaA adjusts its 2018 revenue growth target and confirms its net income growth target 22-Apr-2018 / 16:52 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely respons...

Saturday 21st April 2018

Fresenius Medical Care optimizes its U.S. Care Coordination portfolio and sells Sound Inpatient Physicians Holdings for $2.15 billion

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Disposal/Investment 21.04.2018 / 15:08 The issuer is solely responsible for the content of this announcement. April 21, 2018 Fresenius Medical Care optimizes its U.S. Care Coordination portfolio and sells Sound Inpatient Physicians Holdings for $2.15 billion Fresenius Medical Care, the world's largest provider of dialysis ...

Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care sells Sound Inpatient Physicians Holdings for $2.15 billion

Fresenius Medical Care AG & Co. KGaA / Key word(s): Disposal/Investment Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care sells Sound Inpatient Physicians Holdings for $2.15 billion 21-Apr-2018 / 14:47 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely res...

Friday 20th April 2018

Chief Executive Officer of MOLOGEN AG will not extend Executive Board mandate expiring in October 2018

MOLOGEN AG / Key word(s): Change of Personnel Chief Executive Officer of MOLOGEN AG will not extend Executive Board mandate expiring in October 2018 20-Apr-2018 / 19:14 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement...

Dermapharm Holding SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

Dermapharm Holding SE / Preliminary announcement on the disclosure of financial statements 20.04.2018 / 15:27 Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ---------------------------...

Epigenomics AG: Announcement of the Convening of the General Meeting in Berlin on 30.05.2018 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution

DGAP-News: Epigenomics AG / Announcement of the Convening of the General Meeting 20.04.2018 / 15:04 Announcement according to article 121 AktG (German Stock Companies Act), transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Epigenomics AG announces the convening of the General Meeting. Please findthe full text of the a...

Hardman & Co Research: ValiRx (VAL): 2017: a pivotal year

Hardman & Co Research 20-Apr-2018 / 10:43 GMT/BST Hardman & Co Research: 2017: a pivotal year ValiRx (VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company's two leading assets are in clinical trials: VAL201 (Phase I/II) - a peptide for advanced prostate cancer and potential to treat other hormone- induc...

Siemens Healthineers AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

Siemens Healthineers AG / Preliminary announcement on the disclosure of financial statements 20.04.2018 / 10:00 Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. -------------------------...

Formycon AG: Formycon Ranks 7th in the Financial Times List of Europe's 1000 Strongest-Growing Companies

DGAP-News: Formycon AG / Key word(s): Miscellaneous 20.04.2018 / 08:00 The issuer is solely responsible for the content of this announcement. Press Release // April 20, 2018 Formycon Ranks 7th in the Financial Times List of Europe's 1000 Strongest-Growing Companies - Biosimilars developer impresses with sustained sales growth - Only biotech company in Europe's top ten

Thursday 19th April 2018

Pharnext to Showcase PLEOTHERAPYTM R&D Platform at the 8th Annual Global Orphan Drug Conference

DGAP-News: Pharnext S.A. / Key word(s): Conference 19.04.2018 / 17:45 The issuer is solely responsible for the content of this announcement. Pharnext to Showcase PLEOTHERAPYTM R&D Platform at the 8th Annual Global Orphan Drug Conference   PARIS, France, 5:45 pm, April 19, 2018 (CEST) - Pharnext SA (FR00

RHÖN-KLINIKUM AG: Supervisory Board comments on article in manager magazin

DGAP-News: RHÖN-KLINIKUM AG / Key word(s): Statement/Statement 19.04.2018 / 16:22 The issuer is solely responsible for the content of this announcement. Corporate News Bad Neustadt Neustadt / Saale | 19 April 2018 Supervisory Board of RHÖN-KLINIKUM AG comments on article in manager magazin manager magazin (5/2018 issue) reports as follows in its article "Kranke Kultur" (English: s...

Biofrontera AG:

DGAP-News: Biofrontera AG / Key word(s): Final Results 19.04.2018 / 16:20 The issuer is solely responsible for the content of this announcement. Biofrontera Announces Conference Call to Discuss Financial Results 2017 Leverkusen, Germany, April 19, 2018 - Biofrontera AG (Nasdaq ticker symbol: BFRA; ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, will b...

MOLOGEN presented strong EnanDIM TME Data at AACR 2018

DGAP-News: MOLOGEN AG / Key word(s): Conference 19.04.2018 / 09:56 The issuer is solely responsible for the content of this announcement. PRESS RELEASE N 8 / 2018 of 19/04/2018 MOLOGEN presented strong EnanDIM(R) TME Data at AACR 2018 Berlin, 19 April 2018 - The biopharmaceutical company MOLOGEN AG presented data of its EnanDIM(R) molecules, a new generation of potent non chemically-m...

Hardman & Co Research: Alliance Pharma (APH): Entering the US market

Hardman & Co Research 19-Apr-2018 / 07:15 GMT/BST Hardman & Co Research: Entering the US market Alliance Pharma (APH) is continuing with its buy-and-build strategy having evolved through 35 acquisitions over a period of 20 years into a profitable, cash-generative, specialty pharma business. The company has a mix of international growth brands -Kelo-cote and MacuShield - and a bedrock...

4SC AG: Phase II study of 4SC's resminostat in biliary tract cancer in Japan is initiated

DGAP-News: 4SC AG / Key word(s): Study 19.04.2018 / 07:30 The issuer is solely responsible for the content of this announcement. Phase II study of 4SC's resminostat in biliary tract cancer in Japan is initiated Final results are expected to be available by mid-2020.   Planegg-Martinsried, Germany, 19 April 2018 - 4SC AG (4SC, FSE Prime Standard: VSC) today announced, that a Phas...

U.S. FDA grants Fast Track designation for Polyphor's innovative immuno-oncology candidate balixafortide in combination with eribulin as third line therapy for metastatic breast cancer

EQS Group-News: Polyphor AG / Key word(s): Interim Report/Interim Report 19.04.2018 / 07:00 Allschwil, Switzerland, April 19, 2018 Polyphor announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its novel immuno-oncology candidate balixafortide (POL6326), in combination with eribulin, for the treatment of patients with HER2-negative metas...

STRATEC reports significant growth in sales and earnings in 2017

DGAP-News: STRATEC Biomedical AG / Key word(s): Final Results/Forecast 19.04.2018 / 06:54 The issuer is solely responsible for the content of this announcement. STRATEC reports significant growth in sales and earnings in 2017 - Consolidated sales up 13.4% at EUR 209.8 million in 2017 (previous year: EUR 184.9 million) - Adjusted EBIT rises 10.1% to EUR 35.5 million in 2017 (previous yea...

Epigenomics AG: Blood test shows promise in the detection of liver cancer

DGAP-News: Epigenomics AG / Key word(s): Study results 19.04.2018 / 06:40 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG: Blood test shows promise in the detection of liver cancer - Results from two clinical studies demonstrate high sensitivity and specificity of mSEPT9 blood test - mSEPT9 test exhibited higher diagnostic accuracy ...

Wednesday 18th April 2018

MorphoSys Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Corporate Action 18.04.2018 / 23:26 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, April 18, 2018 MorphoSys Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today the pricing of ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks